<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098656</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-21081</org_study_id>
    <secondary_id>EU-21020</secondary_id>
    <secondary_id>2009-011020-65</secondary_id>
    <secondary_id>CELGENE-EORTC-21081</secondary_id>
    <nct_id>NCT01098656</nct_id>
  </id_info>
  <brief_title>Lenalidomide Maintenance Post-debulking in Advanced CTCL</brief_title>
  <official_title>A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Observation is watching a patient's condition but not giving treatment unless&#xD;
      symptoms appear or change. Lenalidomide may stop the growth of cancer cells by blocking blood&#xD;
      flow to the cancer. It is not yet known whether observation or lenalidomide is more effective&#xD;
      in treating patients who are in complete or partial response after receiving previous&#xD;
      gemcitabine hydrochloride or doxorubicin hydrochloride liposome for cutaneous T-cell lymphoma&#xD;
      or mycosis fungoides/Sézary syndrome.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying observation to see how well it works&#xD;
      compared with lenalidomide in treating patients who are in complete or partial response after&#xD;
      receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for stage&#xD;
      IIB, stage III, or stage IV cutaneous T-cell lymphoma or stage IIB, stage III, or stage IV&#xD;
      mycosis fungoides/Sézary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine if observation versus lenalidomide maintenance therapy after debulking with&#xD;
           gemcitabine hydrochloride or pegylated liposomal doxorubicin hydrochloride with or&#xD;
           without radiotherapy prolongs progression-free survival of patients with advanced stage&#xD;
           IIIB or IV T-cell cutaneous lymphoma or mycosis fungoides/Sézary syndrome not previously&#xD;
           treated with other intravenous chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to institution,&#xD;
      response to debulking treatment (complete response vs partial response), and disease (mycosis&#xD;
      fungoides [MF] vs erythrodermic MF/Sézary syndrome). Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Beginning 4-6 weeks after completion of prior debulking therapy, patients undergo&#xD;
           observation for 560 days.&#xD;
&#xD;
        -  Arm II: Beginning 4-6 weeks after completion of prior debulking therapy, patients&#xD;
           receive oral lenalidomide once a day on days 1-21. Treatment repeats every 28 days for&#xD;
           20 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 12 weeks&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment prematurely halted following company's decision to stop financial support to the&#xD;
    study&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival as assessed by hematogenous disease criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occurrence of second cancers at any site</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.&#xD;
Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)</description>
    <arm_group_label>lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnoses of advanced T-cell cutaneous lymphoma or mycosis fungoides/Sézary syndrome&#xD;
&#xD;
               -  Stage IIB-IV disease&#xD;
&#xD;
          -  Achieved complete or partial response after undergoing prior debulking therapy with 1&#xD;
             of the following recommended* regimens with or without radiotherapy**:&#xD;
&#xD;
               -  Gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of a 28-day&#xD;
                  course at a dose of 1,000 to 1,200 mg/m² for a total of four courses&#xD;
&#xD;
               -  Pegylated liposomal doxorubicin hydrochloride IV over 1 hour on days 1 and 15 of&#xD;
                  a 28-day course at a dose of 20 mg/m² for a total of four courses NOTE: *These&#xD;
                  recommended regimens can be altered according to local institutional policies. In&#xD;
                  case of drug intolerance, the study regimen can be switched from one regimen to&#xD;
                  the other.&#xD;
&#xD;
        NOTE: **Local low-dose/energy-ionizing radiation therapy allowed as part of the debulking&#xD;
        process to treat lesions that do not respond after 3 courses of debulking chemotherapy.&#xD;
&#xD;
          -  Sézary cell burden must be decreased by at least 50% after debulking in patients with&#xD;
             Sézary syndrome&#xD;
&#xD;
          -  Disease not appropriate for skin-directed therapy per local institution standards&#xD;
&#xD;
          -  No disease progression between registration and randomization&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 12 months&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 60 x 10^9/L&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (UNL)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times UNL&#xD;
&#xD;
          -  ALT/AST ≤ 3 times UNL&#xD;
&#xD;
          -  Electrolytes (including sodium, potassium, and chloride) normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Uric acid and calcium normal&#xD;
&#xD;
          -  Free T4 and TSH ≤ 1.5 times ULN&#xD;
&#xD;
          -  Patients with a buffer range from the normal values of +/- 10% for hematology and&#xD;
             biochemistry are acceptable&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 4 weeks prior to, during, and for 4&#xD;
             weeks after completion of study therapy&#xD;
&#xD;
          -  Males must agree not to donate semen during and for 1 week after completion of study&#xD;
             therapy&#xD;
&#xD;
          -  Patients with high risk for or history of a thromboembolic event must agree to receive&#xD;
             prophylactic anticoagulation therapy (e.g., vitamin K) to keep INR in the range of 2-3&#xD;
&#xD;
          -  No New York Heart Association class III-IV disease&#xD;
&#xD;
          -  No blood donating during and for 1 week after completion of study therapy&#xD;
&#xD;
          -  No uncontrolled infectious disease, autoimmune disease, or immunodeficiency&#xD;
&#xD;
          -  No second malignancies within the past 3 years except surgically cured carcinoma in&#xD;
             situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b&#xD;
             prostate cancer, and basal or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  No Lapp lactase deficiency or history of glucose-galactose malabsorption&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other prior intravenous chemotherapy for this cancer&#xD;
&#xD;
               -  For purposes of this protocol, the definition of intravenous chemotherapy also&#xD;
                  includes denileukin diftitox, antibodies, or antibody conjugates&#xD;
&#xD;
          -  No prior splenectomy or splenic irradiation&#xD;
&#xD;
          -  No concurrent topical corticosteroids&#xD;
&#xD;
               -  Concurrent systemic corticosteroids allowed for treatment of tumor flare&#xD;
                  reactions&#xD;
&#xD;
          -  No radiation or drug-based therapy (including steroids) between registration and&#xD;
             randomization&#xD;
&#xD;
          -  No other concurrent drugs (including steroids) during the debulking regimen&#xD;
&#xD;
               -  Low-dose steroids as premedication allowed at the investigator's discretion&#xD;
&#xD;
          -  No other concurrent anticancer treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine Bagot, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Saint-Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna - General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St. Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinky University Central Hospital - Skin &amp; Allergy Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Cedex 1</state>
        <zip>66003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux - Hopital Du Haut Leveque</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac Cedex</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lyon - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <state>Pierre-Benite Cedex</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens - Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg Universitaetskliniken</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csu de Bellvitge (Institut Catala D'Oncologia)</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zurich - Division of Oncology</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy'S and St Thomas' Nhs - St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Nhs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital campus</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>April 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2010</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

